Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Factors Associated with Success of Switching to Faricimab for Neovascular Age-Related Macular Degeneration Refractory to Intravitreal Aflibercept

Akira Machida
ORCID logo ,
Akio Oishi
* ORCID logo ,
Junichiro Ikeda
,
Junko Kurihara
,
Ai Yoneda
,
Eiko Tsuiki
,
Yuki Hirata
,
Ryuya Murakami
,
Takashi Kitaoka
Version 1 : Received: 9 January 2024 / Approved: 9 January 2024 / Online: 9 January 2024 (15:53:57 CET)

A peer-reviewed article of this Preprint also exists.

Machida, A.; Oishi, A.; Ikeda, J.; Kurihara, J.; Yoneda, A.; Tsuiki, E.; Hirata, Y.; Murakami, R.; Kitaoka, T. Factors Associated with Success of Switching to Faricimab for Neovascular Age-Related Macular Degeneration Refractory to Intravitreal Aflibercept. Life 2024, 14, 476. Machida, A.; Oishi, A.; Ikeda, J.; Kurihara, J.; Yoneda, A.; Tsuiki, E.; Hirata, Y.; Murakami, R.; Kitaoka, T. Factors Associated with Success of Switching to Faricimab for Neovascular Age-Related Macular Degeneration Refractory to Intravitreal Aflibercept. Life 2024, 14, 476.

Abstract

To investigate factors associated with the success of switching to faricimab for type 1 macular neovascularization (MNV) refractory to intravitreal aflibercept (IVA). This retrospective cohort study included patients with type 1 MNV who were switched to faricimab because they were refractory to IVA at two centers. The main outcome was an extension of the treatment interval after 6 months, and factors related to the success or failure of the extension and visual and anatomical outcomes were assessed. The analysis included 43 eyes of 43 patients. Extended dosing intervals of more than 2 weeks were identified in 14 eyes (32.6%). A short dosing interval before the switch, the absence of polypoidal lesions, and a thin central choroidal thickness before the switch were identified as factors involved in successful extension. For patients with refractory type 1 MNV, switching to faricimab is a safe and potential option to extend from existing dosing intervals.

Keywords

Age-related macular degeneration (AMD); Anti-vascular endothelial growth factor (VEGF) treatment; Drug switch; Intravitreal aflibercept (IVA); Intravitreal faricimab (IVF); Macular neovascularization (MNV); Polypoidal choroidal vasculopathy (PCV); Real-world date; Refractory cases; Treat-and-extend (TAE) regimen

Subject

Medicine and Pharmacology, Ophthalmology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.